Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04838444
PHASE3

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

Sponsor: Valneva Austria GmbH

View on ClinicalTrials.gov

Summary

In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).

Official title: An Open-Label, Single Arm Trial To Evaluate Antibody Persistence And Long Term Safety Of A Live-Attenuated Chikungunya Virus Vaccine (VLA1553) In Adults Aged 18 Years and Above

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

363

Start Date

2021-04-02

Completion Date

2031-05

Last Updated

2025-12-24

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

VLA1553

Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.

Locations (10)

Accelerated Enrollment Solutions (AES)

Phoenix, Arizona, United States

Velocity Clinical Research

Hallandale, Florida, United States

Accelerated Enrollment Solutions (AES)

Chicago, Illinois, United States

Alliance for Multispecialty Research (AMR)

Lexington, Kentucky, United States

Velocity Clinical Research

Grand Island, Nebraska, United States

Velocity Clinical Research

Omaha, Nebraska, United States

Alliance for Multispecialty Research (AMR)

Knoxville, Tennessee, United States

Velocity Clinical Research

Austin, Texas, United States

Velocity Clinical Research

West Jordan, Utah, United States

Allliance for Multispecialty Research (AMR)

Norfolk, Virginia, United States